Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
- Conditions
- LymphomaLeukemiaCancer
- Registration Number
- NCT00105313
- Lead Sponsor
- MedImmune LLC
- Brief Summary
For primary objectives, we will determine the MTD and examine clinical responses and immune cell populations to determine an OBD, and describe the safety and tolerability of MEDI-507.
For the secondary objectives we will look at the antitumor activity of MEDI 507, PK, serum concentrations, and immunogenicity of MEDI-507, as well as time courses of depletion and recovery of CD2 positive and total T-Cell populations.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 80
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method To determine the maximum tolerated dose (MTD) or the optimal biological dose (OBD) of MEDI-507 based on safety and tolerability of MEDI-507 in patients with CD-2 positive lymphoproliferative disorders.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (11)
USC/Norris Cancer Center
🇺🇸Los Angeles, California, United States
Yale Cancer Center
🇺🇸New Haven, Connecticut, United States
Georgetown University Medical Center, Lombardi Comprehensive Cancer Center
🇺🇸Washington, District of Columbia, United States
University of Maryland School of Medicine, Greenebaum Cancer Center
🇺🇸Baltimore, Maryland, United States
Nevada Cancer Institute
🇺🇸Las Vegas, Nevada, United States
Wake Forest University Health Sciences
🇺🇸Winston-Salem, North Carolina, United States
Kimmel Cancer Center, Thomas Jefferson University
🇺🇸Philadelphia, Pennsylvania, United States
M.D. Anderson Cancer Center
🇺🇸Houston, Texas, United States
Washington University
🇺🇸St. Louis, Missouri, United States
Tufts New England Medical Center
🇺🇸Boston, Massachusetts, United States
H. Lee Moffitt Cancer Ctr & Research Institute Div of Hem/Onc
🇺🇸Tampa, Florida, United States